Samelisant
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02342041)
Timeline
Indications
Mechanism of action
- Histamine H3 receptorINHIBITOR
HRH3 inhibitor
- Histamine H3 receptorINVERSE AGONIST
Histamine H3 receptor inverse agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CN1CCOCC1)Nc1ccc(OC2CCN(C3CCC3)CC2)cc1- Mol. weight
- 373.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297328 ↗
Also known as
- suvn-g3031
- suvn-g3031
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04072380 | Phase 2 | Aug 31, 2019 | Suven Life Sciences Limited |
| NCT02881294 | Phase 1 | Aug 1, 2016 | Suven Life Sciences Limited |
| NCT02342041 | Phase 1 | Sep 1, 2014 | Suven Life Sciences Limited |
| NCT05530447 | N/A | — | Suven Life Sciences Limited |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suven Life Sciences Limited | For profit | 4 | 4 | 3 | 2014 |
1 organizations
Page 1 / 1